Allergan Buys Bonti, Releases New Data In Defense Of 'Iconic' Botox Brand
Allergan declared that no other brand is more 'iconic' than Botox, during its medical aesthetics investor event, but the company also revealed several defensive moves to protect the neurotoxin's status, including the acquisition of fast-acting, short duration toxin maker Bonti.
You may also be interested in...
AbbVie Updates Exec Team, Creates A Separate Aesthetics Business Unit
The only addition to AbbVie’s leadership after it closes the $63bn acquisition of Allergan will be Carrie Strom, who will lead the Allergan Aesthetics business.
Allergan’s Botox Gains Continue, Pipeline Progresses Ahead Of AbbVie Merger
Key Allergan drugs performed well in Q3 and pipeline programs are approaching milestones as AbbVie says its $63bn acquisition of the company remains on track to close early next year.
AbbVie Will Use Allergan Revenue To Fund Combined Firm's Large R&D Pipeline
While AbbVie said its $63bn purchase places little value on Allergan's R&D pipeline, the companies have 62 drugs in clinical development with 38 in Phase II and III or filed with regulators, including new indications for approved products.